Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.

PURPOSE Reverse transcriptase (RT) polymerase chain reaction (PCR) with multiple markers has been demonstrated to be highly sensitive in detecting circulating cells from patients with malignant melanoma (MM). We evaluated the clinical significance of the presence in peripheral blood of specific PCR-positive mRNA markers as an expression of circulating melanoma cells. PATIENTS AND METHODS Total cellular RNA was obtained from the peripheral blood of 235 patients with either localized (n = 154) or metastatic (n = 81) melanoma. We performed RT-PCR using tyrosinase, p97, MUC18, and MelanA/MART1 as gene markers. The PCR products were analyzed by gel electrophoresis and Southern blot hybridization. In addition, 20 healthy subjects and 21 patients with nonmelanoma cancer were used as negative controls. RESULTS Although detected at various levels among assessable patients, each mRNA marker was significantly correlated with disease stage. A significant correlation with disease stage was demonstrated for patients who were positive to all four markers (P < .0001) or to at least three markers (P < .001). Univariate analysis showed a significant correlation between risk of recurrence (evaluated in stage I, II, and III patients) and increasing number of PCR-positive markers (P = .0002). Logistic regression multivariate analysis indicated that each single marker (except tyrosinase) and, more especially, the presence of four PCR-positive markers remained statistically independent prognostic factors for tumor progression. CONCLUSION Our data establish the existence of a significant correlation among clinical stages, tumor progression, and presence of circulating melanoma-associated antigens in peripheral blood of MM patients. Preliminary assessment of a subset of patients with a higher risk of recurrence needs longer follow-up and further studies to define the role of RT-PCR in monitoring MM patients.

[1]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[2]  A. Hauschild,et al.  Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  U. Reinhold,et al.  The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. , 1997, The Journal of investigative dermatology.

[4]  T. Wobbes,et al.  Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. , 1997, Cancer research.

[5]  L. Xerri,et al.  Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. , 1995, Archives of dermatology.

[6]  A. Ganser,et al.  Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. , 1996, Journal of the National Cancer Institute.

[7]  D. Colomer,et al.  Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Scheibenbogen,et al.  Detection of Residual Tumor Cells in Patients with Malignant Melanoma Responding to Immunotherapy , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[9]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[10]  C. Scheibenbogen,et al.  Hematogenous spread of malignant melanoma cells in different stages of disease. , 1993, The Journal of investigative dermatology.

[11]  A. Foss,et al.  The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. , 1995, British Journal of Cancer.

[12]  M. Gore,et al.  Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  J. Lehmann,et al.  MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[14]  W. Dreyer,et al.  Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.

[16]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[17]  K. Pittman,et al.  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction , 1991, The Lancet.

[18]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[19]  D. Hunt,et al.  Direct analysis of tumor-associated peptide antigens. , 1994, Current opinion in immunology.

[20]  C. Scheibenbogen,et al.  A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. , 1995, Cancer research.

[21]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[22]  M. Ross,et al.  Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. N. Epstein,et al.  A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.

[24]  D. Garrison,et al.  Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  N. Brouwenstijn,et al.  Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. , 1997, British Journal of Cancer.

[26]  D. Garrison,et al.  Melanoma-associated antigens as messenger RNA detection markers for melanoma. , 1997, Cancer research.

[27]  E. Levine,et al.  Detection of tyrosinase mRNA from the blood of melanoma patients. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  A. Poustka,et al.  YAC contig organization and CpG island analysis in Xq28. , 1994, Genomics.